Proinflammatory cytokines, adiponectin, and increased risk of primary cardiovascular events in diabetic patients with or without renal dysfunction: Results from the ESTHER study

Diabetes Care

Volumn 36, Issue 6, 2013, Pages 1703-1711

  Schöttker, Ben ^a   Herder, Christian ^b   Rothenbacher, Dietrich ^a,c   Roden, Michael ^b,d   Kolb, Hubert ^b   Müller, Heiko ^a   Brenner, Hermann ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 18; INTERLEUKIN 6; LEPTIN; MACROPHAGE MIGRATION INHIBITION FACTOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; FATALITY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEDIATOR; POPULATION RESEARCH; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

ADIPONECTIN; AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CYTOKINES; DIABETIC RETINOPATHY; FEMALE; HUMANS; INTERLEUKIN-18; INTERLEUKIN-6; LEPTIN; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS;

EID: 84878254588     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1416     Document Type: Article

References (40)

1. Kaptoge S, Di Angelantonio E, Lowe G, et al.; Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-140
2. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008;5:e78
3. Whiteley W, Jackson C, Lewis S, et al. Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6. PLoS Med 2009;6:e1000145
4. Curb JD, Abbott RD, Rodriguez BL, et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 2003;107:2016-2020 (Pubitemid 36506076)
5. Best LG, Zhang Y, Lee ET, et al. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation 2005;112:1289-1295 (Pubitemid 41266723)
6. Soinio M, Marniemi J, Laakso M, Lehto S, Rönnemaa T. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care 2006;29:329-333 (Pubitemid 44106513)
7. Bruno G, Fornengo P, Novelli G, et al. C-reactive protein and 5-year survival in type 2 diabetes: the Casale Monferrato Study. Diabetes 2009;58:926-933
8. Lee S, Kim IT, Park HB, et al. High-sensitivity C-reactive protein can predict major adverse cardiovascular events in Korean patients with type 2 diabetes. J Korean Med Sci 2011;26:1322-1327
9. Trøseid M, Seljeflot I, Hjerkinn EM, Arnesen H. Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: synergistic effect of inflammation and hyperglycemia. Diabetes Care 2009;32:486-492
10. Rathmann W, Herder C. Adiponectin and cardiovascular mortality: evidence for "reverse epidemiology". Horm Metab Res 2007;39:1-2 (Pubitemid 46535148)
11. Sattar N, Nelson SM. Adiponectin, diabetes, and coronary heart disease in older persons: unraveling the paradox. J Clin Endocrinol Metab 2008;93:3299-3301
12. Raum E, Rothenbacher D, Löw M, Stegmaier C, Ziegler H, Brenner H. Changes of cardiovascular risk factors and their implications in subsequent birth cohorts of older adults in Germany: a life course approach. Eur J Cardiovasc Prev Rehabil 2007;14:809-814 (Pubitemid 350197011)
13. Herder C, Schöttker B, Rothenbacher D, et al. Interleukin-6 in the prediction of primary cardiovascular events in diabetes patients: results from the ESTHER study. Atherosclerosis 2011;216:244-247
14. Schöttker B, Herder C, Müller H, Brenner H, Rothenbacher D. Clinical utility of creatinine- and cystatin C-based definition of renal function for risk prediction of primary cardiovascular events in patients with diabetes. Diabetes Care 2012;35:879-886
15. Inker LA, Eckfeldt J, Levey AS, et al. Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values. Am J Kidney Dis 2011;58:682-684
16. Murdolo G, Nowotny B, Celi F, et al. Inflammatory adipokines, high molecular weight adiponectin, and insulin resistance: a population-based survey in prepubertal schoolchildren. PLoS ONE 2011;6:e17264
17. Herder C, Illig T, Baumert J, et al. Macrophage migration inhibitory factor (MIF) and risk for coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Atherosclerosis 2008;200:380-388
18. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004;65:1009-1016 (Pubitemid 38251077)
19. Tonelli M, Muntner P, Lloyd A, et al.; Alberta Kidney Disease Network. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012;380:807-814
20. Kengne AP, Batty GD, Hamer M, Stamatakis E, Czernichow S. Association of C-reactive protein with cardiovascular disease mortality according to diabetes status: pooled analyses of 25,979 participants from four U.K. prospective cohort studies. Diabetes Care 2012;35:396-403
21. Sattar N, Wannamethee G, Sarwar N, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation 2006;114:623-629 (Pubitemid 44252303)
22. Karakas M, Zierer A, Herder C, et al. Leptin, adiponectin, their ratio and risk of Coronary Heart Disease: results from the MONICA/KORA Augsburg Study 1984-2002. Atherosclerosis 2010;209:220-225
23. Frystyk J, Berne C, Berglund L, Jensevik K, Flyvbjerg A, Zethelius B. Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men. J Clin Endocrinol Metab 2007;92:571-576
24. Pischon T, Hu FB, Girman CJ, et al. Plasma total and high molecular weight adiponectin levels and risk of coronary heart disease in women. Atherosclerosis 2011;219:322-329
25. Dekker JM, Funahashi T, Nijpels G, et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 2008;93:1489-1496 (Pubitemid 351519753)
26. Schnabel R, Messow CM, Lubos E, et al. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. Eur Heart J 2008;29:649-657
27. Beatty AL, Zhang MH, Ku IA, Na B, Schiller NB, Whooley MA. Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: data from the Heart and Soul Study. Atherosclerosis 2012;220:587-592
28. Menon V, Li L, Wang X, et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2599-2606 (Pubitemid 44300977)
29. Jorsal A, Tarnow L, Frystyk J, et al. Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int 2008;74:649-654
30. Thorand B, Kolb H, Baumert J, et al. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984-2002. Diabetes 2005;54:2932-2938 (Pubitemid 41401089)
31. Welsh P, Woodward M, Rumley A, MacMahon S, Lowe GD. Does interleukin-18 or tumour necrosis factor-alpha have an independent association with the risk of coronary heart disease? Results from a prospective study in New Zealand. Cytokine 2010;50:94-98
32. Blankenberg S, Luc G, Ducimetière P, et al.; PRIME Study Group. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003;108:2453-2459 (Pubitemid 37444405)
33. Koenig W, Khuseyinova N, Baumert J, et al. Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol 2006;26:2745-2751
34. Woodward M, Welsh P, Rumley A, Tunstall-Pedoe H, Lowe GD. Do inflammatory biomarkers add to the discrimination of cardiovascular disease after allowing for social deprivation? Results froma 10-year cohort study in Glasgow, Scotland. Eur Heart J 2010;31:2669-2675
35. Blankenberg S, Tiret L, Bickel C, et al.; AtheroGene Investigators. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;106:24-30 (Pubitemid 34747437)
36. Espinola-Klein C, Rupprecht HJ, Bickel C, et al.; Athero Gene Investigators. Impact of inflammatory markers on cardiovascular mortality in patients with metabolic syndrome. Eur J Cardiovasc Prev Rehabil 2008;15:278-284
37. Stott DJ, Welsh P, Rumley A, et al. Adipocytokines and risk of stroke in older people: a nested case-control study. Int J Epidemiol 2009;38:253-261
38. Hartford M, Wiklund O, Hultén LM, et al. Interleukin-18 as a predictor of future events in patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol 2010;30:2039-2046
39. Boekholdt SM, Peters RJ, Day NE, et al. Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk Prospective Population study. Am J Med 2004;117:390-397 (Pubitemid 39369543)
40. Makino A, Nakamura T, Hirano M, et al. High plasma levels of macrophage migration inhibitory factor are associated with adverse long-term outcome in patients with stable coronary artery disease and impaired glucose tolerance or type 2 diabetes mellitus. Atherosclerosis 2010;213:573-578